Cellworks Expands Evidence for Predicting Chemo-Immunotherapy Benefit in NSCLC with New Early-Stage Disease Study
New study presented at AACR 2026 supports the predictive validly of Cellworks’ mechanistic AI platform in early-stage NSCLC SAN DIEGO, CA, UNITED STATES, April 22, 2026 /EINPresswire.com/ -- Cellworks Group Inc., the leader in Personalized …